CME Group filed a lawsuit against the U.S. Commodity Futures Trading Commission (CFTC) on Thursday, arguing the regulator erred in approving Kalshi’s first U.S. perpetual futures product. The case sets up a high-stakes test of how novel derivatives are reviewed and approved in the United States.
The Dispute
According to the complaint, CME Group contends the CFTC’s decision to approve a perpetual futures contract from Kalshi was improper. The exchange operator argues the agency’s review and approval process was flawed, challenging both the substance and procedure of the determination.
Background on the Parties and Product
CME Group is one of the world’s largest derivatives marketplaces, offering futures and options across asset classes. The CFTC is the federal regulator responsible for overseeing U.S. futures and swaps markets. Kalshi is a CFTC-regulated exchange that lists derivatives contracts.
Perpetual futures are derivatives that do not have an expiration date, instead using periodic funding payments to keep prices anchored to an underlying reference. While widely used in global digital asset markets, perpetual futures have had limited availability on U.S.-regulated venues, making the CFTC’s approval of a listed product a notable development.
Why It Matters
The lawsuit could influence how U.S. regulators evaluate and supervise new derivatives structures, including perpetual futures. A court decision may clarify the standards applied to exchanges seeking to list innovative contracts and shape competitive dynamics among U.S. derivatives venues.
What Comes Next
The case will proceed through the courts, with further filings and responses expected. Its outcome may set an important precedent for future CFTC reviews of novel derivatives products and for market participants seeking to expand U.S.-listed offerings.